Publicacións en colaboración con investigadores/as de Asan Medical Center (2)

2024

  1. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

2020

  1. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 11, pp. 1132-1143